Serina Therapeutics Inc
SER2.280USD
-0.090-3.80%
交易中 （美东）报价延迟15分钟
24.04M总市值
亏损市盈率 TTM
关于 Serina Therapeutics Inc 公司
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc简介
公司代码SER
公司名称Serina Therapeutics Inc
上市日期Nov 29, 2018
CEOLedger (Steven)
员工数量12
证券类型Ordinary Share
年结日Nov 29
公司地址601 Genome Way,
城市HUNTSVILLE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编35806
电话12563279630
网址https://serinatherapeutics.com/
公司代码SER
上市日期Nov 29, 2018
CEOLedger (Steven)
Serina Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
其他
51.65%
持股股东
持股股东
占比
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
其他
51.65%
股东类型
持股股东
占比
Corporation
39.12%
Individual Investor
8.18%
Investment Advisor
2.92%
Hedge Fund
0.78%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.02%
其他
48.43%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
56
455.00K
4.27%
-38.88K
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Juvenescence Ltd
3.27M
30.64%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.49%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.64%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
180.01K
1.69%
+29.39K
+19.51%
Sep 30, 2025
Ledger (Steven A)
95.73K
0.9%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
83.19K
0.78%
-2.02K
-2.38%
Sep 30, 2025
Waverly Advisors, LLC
67.49K
0.63%
--
--
Sep 30, 2025
Bailey (Gregory Hugh)
67.24K
0.63%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
29.61K
0.28%
+724.00
+2.51%
Sep 30, 2025
Linscomb & Williams, Inc.
18.80K
0.18%
+18.80K
--
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
公告日期
除权除息日
类型
比率
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
